COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00681226




Registration number
NCT00681226
Ethics application status
Date submitted
20/05/2008
Date registered
21/05/2008
Date last updated
5/04/2012

Titles & IDs
Public title
Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease
Scientific title
ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease
Secondary ID [1] 0 0
273/06
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ramipril or matching placebo

Treatment: Drugs: Ramipril or matching placebo
10 mg Ramipril or matching placebo once daily for 6 months

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
walking time
Timepoint [1] 0 0
baseline and 6 months
Secondary outcome [1] 0 0
walking impairment questionnaire
Timepoint [1] 0 0
baseline and 6 months

Eligibility
Key inclusion criteria
- Ankle brachial index of <0.9 in at least one leg

- History of intermittent claudication (unilateral or bilateral)

- A stable medication regimen for at least 6 months
Minimum age
40 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Limiting coronary artery disease

- Renal failure (serum creatinine > 0.20 mmol/L)

- Current treatment or treatment within the previous 6 months with ACE inhibitors or
angiotensin II receptor antagonists

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Baker Heart Research Institute - Melbourne
Recruitment postcode(s) [1] 0 0
8008 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Bayside Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our
preliminary findings indicate that the drug ramipril is much more effective in improving
walking ability than current therapies. To be accepted as a new treatment for PAD these
findings require validation in a much larger clinical trial.We propose to examine the effects
of ramipril therapy for 6 months in a randomized, controlled trial of patients with PAD. If
positive, this study will identify ramipril as a potential new therapy for PAD.
Trial website
https://clinicaltrials.gov/show/NCT00681226
Trial related presentations / publications
Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006 May 2;144(9):660-4. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.
Public notes

Contacts
Principal investigator
Name 0 0
Bronwyn A Kingwell, PhD
Address 0 0
Baker Heart Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications